Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Latest News about ESALF
Recent news which mentions ESALF
< Previous
1
2
Next >
FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval
June 08, 2023
Tickers
BIIB
ESALF
ESALY
Tags
Market News
Benzinga
FDA
From
Benzinga
Medicare unveils plan for coverage of new Alzheimer’s drugs
June 01, 2023
Tickers
BIIB
ESALF
LLY
Tags
BIIB
LLY
ESALF
From
MarketWatch
Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen
May 04, 2023
Tickers
BIIB
ESALF
ESALY
LLY
Tags
ESALY
News
General
From
Benzinga
Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!
April 21, 2023
Tickers
BIIB
ESALF
ESALY
LLY
Tags
ESALF
General
Government
From
Benzinga
Merck, Eisai Shelve Keytruda Plus Lenvima Combo Trial In Skin Cancer Setting, Disappoints In Certain Type Of Colorectal Cancer
April 10, 2023
Tickers
ESALF
ESALY
MRK
Tags
ESALF
General
News
From
Benzinga
National Institute on Aging Aims Building $300M Alzheimer's Research Database
April 03, 2023
Tickers
BIIB
ESALF
ESALY
Tags
Government
General
ESALY
From
Benzinga
Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug
March 31, 2023
Tickers
BIIB
ESALF
ESALY
Tags
ESALY
Biotech
News
From
Benzinga
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
March 16, 2023
Tickers
BIIB
ESALF
ESALY
LLY
Tags
ESALY
Regulations
News
From
Benzinga
Analyst Says Biogen-Eisai's Alzheimer's Treatment Leqembi Coverage Enables Access To Over $2.5B Market Opportunity
March 14, 2023
Tickers
BIIB
ESALF
ESALY
Tags
Large Cap
Biotech
Health Care
From
Benzinga
Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment
March 06, 2023
Tickers
BIIB
ESALF
ESALY
Tags
ESALY
News
Briefs
From
Benzinga
The 7 Best Growth Stocks to Buy for February 2023
February 06, 2023
Tickers
ACLS
CPRX
DAR
ESALF
Tags
ACLS
DAR
ICLR
From
InvestorPlace
New Alzheimer’s drug shows some promise, but has big price tag
February 02, 2023
Tickers
BIIB
ESALF
Tags
ESALF
BIIB
JP:4523
From
MarketWatch
FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway
January 06, 2023
Tickers
BIIB
ESALF
ESALY
Tags
Market News
FDA
Benzinga
From
Benzinga
Biogen's Alzheimer's Antibody Might Have A Third Death Associated With
December 22, 2022
Tickers
BIIB
ESALF
ESALY
Tags
Market News
Benzinga
Large Cap
From
Benzinga
Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug
December 20, 2022
Tickers
CPRX
ESALF
ESALY
Tags
Small Cap
Biotech
CPRX
From
Benzinga
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
November 30, 2022
Tickers
BIIB
ESALF
ESALY
Tags
Market News
Analyst Ratings
Benzinga
From
Benzinga
Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's
November 30, 2022
Tickers
BIIB
ESALF
ESALY
Tags
Market News
Benzinga
Large Cap
From
Benzinga
Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall
November 28, 2022
Tickers
BIIB
ESALF
ESALY
Tags
General
Briefs
why it's moving
From
Benzinga
One Alzheimer’s drug has failed, but investors are still betting on Biogen and Lilly treatments
November 14, 2022
Tickers
BIIB
ESALF
LLY
MOR
Tags
LLY
CH:ROG
PRTA
From
MarketWatch
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
November 14, 2022
Tickers
BIIB
ESALF
ESALY
MOR
Tags
Large Cap
BIIB
Market News
From
Benzinga
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
October 10, 2022
Tickers
BIIB
ESALF
ESALY
LLY
Tags
LLY
Benzinga
Market News
From
Benzinga
Medicare coverage of Eisai and Biogen’s promising new Alzheimer’s therapy is ‘another bridge to cross’
September 28, 2022
Tickers
BIIB
ESALF
SPX
Tags
SPX
ESALF
JP:4523
From
MarketWatch
Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer
September 12, 2022
Tickers
ESALF
ESALY
MRK
Tags
General
ESALY
Briefs
From
Benzinga
Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate
August 25, 2022
Tickers
ESALF
ESALY
LLY
RHHBF
Tags
Price Target
ESALY
Briefs
From
Benzinga
Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal
August 03, 2022
Tickers
ESALF
ESALY
MRK
Tags
ESALY
News
Briefs
From
Benzinga
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
July 06, 2022
Tickers
AMTI
BIIB
ESALF
ESALY
Tags
PHGE
Penny Stocks
Benzinga
From
Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Tickers
AGEN
ARWR
ATNX
AVGR
Tags
ATNX
General
XENE
From
Benzinga
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug
May 10, 2022
Tickers
BIIB
ESALF
ESALY
Tags
Market News
FDA
Benzinga
From
Benzinga
Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab
March 22, 2022
Tickers
BIIB
ESALF
ESALY
Tags
ESALF
ESALY
Briefs
From
Benzinga
FDA Approves Second Indication For Merck's Keytruda In Endometrial Cancer
March 22, 2022
Tickers
ESALF
ESALY
MRK
Tags
Biotech
Health Care
Market News
From
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.